Rankings
▼
Calendar
SUPN FY 2019 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
FY 2019 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$393M
-3.9% YoY
Gross Profit
$376M
95.8% margin
Operating Income
$149M
37.8% margin
Net Income
$113M
28.8% margin
EPS (Diluted)
$2.10
Cash Flow
Operating Cash Flow
$143M
Free Cash Flow
$140M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$565M
Stockholders' Equity
$595M
Cash & Equivalents
$181M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$393M
$409M
-3.9%
Gross Profit
$376M
$394M
-4.4%
Operating Income
$149M
$144M
+2.9%
Net Income
$113M
$111M
+1.9%
← Q4 2018
All Quarters
Q1 2019 →